Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

The Cancer Genome (Q1)


Organizer(s) Elaine R. Mardis, Sohrab Shah and Ben J. Raphael
February 7—11, 2016
Fairmont Banff Springs • Banff, Alberta Canada
Discounted Abstract Deadline: Oct 7, 2015
Abstract Deadline: Nov 9, 2015
Scholarship Deadline: Oct 7, 2015
Discounted Registration Deadline: Dec 7, 2015

Sponsored by Constellation Pharmaceuticals, Incyte Corporation and Roche


Summary of Meeting:
The combination of next-generation sequencing and analysis as applied to experiments studying the cancer genome has revolutionized our understanding of cancer biology. Large-scale cancer genomics has further established a baseline that is now poised to effect the translation of cancer genomics into the clinical setting, effectively transforming patient care. The barriers and challenges to translation are significant, not the least of which involves the transition of research-grade computational and interpretational analysis to clinical-grade analysis. Assays must be highly refined, validated and accurate. How the use of genomic approaches to monitor patient response to therapy, the onset of acquired resistance to therapy and other aspects of patient care will be accepted as a more sensitive partner with conventional imaging approaches must be addressed. Appropriate assignment of therapies to specific gene/protein alterations also will be of paramount importance, especially as the numbers and types of targeted therapies increase. Genomics will also impact our understanding of the immune system's interaction with tumors, leading to the development of personalized vaccine strategies that may provide more durable responses. Specific goals of the meeting include: 1) Providing an overview of computational tools, any gaps in variant detection capabilities and their challenges for clinical implementation; 2) Discussing specific approaches to identify gene-therapy combinations, specifically addressing the difficulty of assessing the impact of DNA mutations on protein function; 3) Identification of the significant efforts ongoing in blood-based ("liquid") biopsy of patients on therapy or following resection surgery; 4) Presentation of current efforts to utilize genomics of individual tumors to inform immunotherapy development; 5) Discussion of efforts at data integration, across "omic" platforms, and also the integration of genomic data with more conventional pathology-based evidence/data. The anticipated outcomes will be the exchange of ideas among international participants on how genomics will impact cancer care and clinical practice and what gaps exist in their existing approaches, as well as development of new collaborations and new enthusiasm for helping to build on the potential of genome-guided approaches to cancer medicine.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, February 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 12 in order to fully experience the meeting.

SUNDAY, FEBRUARY 7

16:00—20:00
Arrival and Registration

Van Horne Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, FEBRUARY 8

07:00—08:00
Breakfast

Mezzanine 2
08:00—09:30
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Elaine Mardis, Washington University School of Medicine, USA

* Michael Snyder, Stanford University School of Medicine, USA

Levi A. Garraway, Dana-Farber Cancer Institute, USA
Sequencing and Clinical Interpretation to Guide Precision Cancer Medicine

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Blockade Therapies: Current Experience and Future Directions

09:30—09:50
Coffee Break

Van Horne Foyer
09:50—11:30
Cancer Genomics: Discovery to Translation (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Michael Snyder, Stanford University School of Medicine, USA

* Elaine Mardis, Washington University School of Medicine, USA
Clinical Translation of Cancer Genomics

David Solit, Memorial Sloan Kettering Cancer Center, USA
Defining the Actionable Genome

Heidi Greulich, Dana-Farber Cancer Institute, USA
Short Talk: Identification of a Novel Cell-Selective Anti-Cancer Modulator of PDE3A by Predictive Chemogenomics

Nolan Priedigkeit, University of Pittsburgh, USA
Short Talk: Transcriptomic Evolution of Fusion Genes in Recurrent Ovarian Cancer

11:30—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
11:30—14:30
On Own for Lunch

14:30—16:30
Panel: Challenges of Precision Oncology in the Clinical Setting (Joint)

Van Horne A/B
Levi A. Garraway, Dana-Farber Cancer Institute, USA

Lillian Siu, Princess Margaret Hospital, Canada

Michael F. Berger, Memorial Sloan Kettering Cancer Center, USA

David Hyman, Memorial Sloan Kettering Cancer Center, USA

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Genome-Guided Cancer Therapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Alexandra Snyder, Memorial Sloan Kettering Cancer Center, USA

Lillian Siu, Princess Margaret Hospital, Canada
Experience from Princess Margaret IMPACT/COMPACT Trial

Nuria Lopez-Bigas, University Pompeu Fabra - UPF, Spain
Cancer Drivers and their Therapeutic Opportunities

Andrew V. Biankin, University of Glasgow, UK
Talk Title to be Announced

Xuan Shirley Li, MolecularMatch, Inc, USA
Short Talk: The MolecularMatch Genotype Based Therapeutics and Clinical Trials Search Engine


Following Session is for Genomics and Personalized Medicine (Q2)

17:00—19:00
Disease Gene Discovery
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne C
* Heidi Rehm, Harvard Medical School, USA

Karen B. Avraham, Tel Aviv University, Israel
Genomics of Hereditary Deafness

Joseph G. Gleeson, HHMI/The Rockefeller University, USA
Genomics and Precision Medicine in Neurodevelopmental Disease

Richard A. Gibbs, Baylor College of Medicine, USA
Expanding the Mendelian View

Ana S.A. Cohen, University of British Columbia, Canada
Short Talk: Exome Sequencing of Patients with Weaver-Like Features Links Another Cancer Gene, EED, to Overgrowth Syndromes

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 1

Mezzanine 2

TUESDAY, FEBRUARY 9

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
Genomics Informs Personalized Immunotherapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* James P. Allison, University of Texas MD Anderson Cancer Center, USA

Robert D. Schreiber, Washington University School of Medicine, USA
Genomic Approaches to Understand Cancer Immunosuppression

Renier Brentjens, Memorial Sloan Kettering Cancer Center, USA
Moving CAR T Cell Therapy Forward: CARs and Armored CARs

Alexandra Snyder, Memorial Sloan Kettering Cancer Center, USA
Beyond Mutational Load in Checkpoint Blockade Therapies and Advanced Solid Tumors

Magali C. Champion, Stanford University, USA
Short Talk: Pancancer Module Analysis Captures Major Oncogenic Pathways and Identifies Master Regulator of Immune Response

Haven Garber, University of Texas MD Anderson Cancer Center, USA
Short Talk: Subclonal Evolution of Chronic Lymphocytic Leukemia (CLL) after Allogeneic T-cell Immunotherapies


Following Session is for Genomics and Personalized Medicine (Q2)

08:00—11:15
Technology and Sensors
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne C
* Leroy E. Hood, Institute for Systems Biology, USA

William J. Greenleaf, Stanford University, USA
Single Cell ATAC-Seq

Ali Torkamani, The Scripps Translational Science Institute & Scripps Research Institute, USA
Genome-Guided Therapy Repurposing and Response Monitoring in Orphan Disease

Jim R. Heath, California Institute of Technology, USA
Affinity Reagents and Sensors

Lars M. Steinmetz, European Molecular Biology Laboratory and Stanford University, Germany
Biosensors for Personal Molecular Monitoring of Health and Disease

Shengxi Guan, New England Biolabs, USA
Short Talk: A Sensitive Approach to Map Genome-wide 5-Hydroxymethylcytosine and 5-Formylcytosine at Single-Base Resolution

Carla Grandori, SEngine Precision Medicine and Cure First, USA
Short Talk: Cross-Cancer Target Identification and Validation through Synthetic Lethality, TCGA Analysis, and Patient Sample Screening

09:20—09:40
Coffee Break

Van Horne Foyer
11:00—14:30
On Own for Lunch

14:30—16:30
Workshop: The Integrative Human Microbiome Project (iHMP): Dynamic Analysis of Microbiome-Host Omics Profiles during Periods of Human Health and Disease (Joint)
The Integrative Human Microbiome Project (iHMP) is the second phase of the National Institute of Health (NIH) Common Fund's Human Microbiome Project (HMP) program. The mission of the overall HMP is to generate resources to permit comprehensive characterization of the human microbiota to further our understanding of how the microbiome impacts human health and disease. In this phase of the program, the iHMP is creating integrated longitudinal datasets of biological properties from both the microbiome and host from three different cohort studies of microbiome-associated conditions using multiple "omics" technologies. Tools, datasets and other resources from the first phase of the project are available at the HMP DACC. During this session, we will provide an overview of the data and resources freely available to the research community as derived from the three iHMP projects: 1) the Multi-Omic Microbiome Study: Pregnancy Initiative (MOMS-PI) at Virginia Commonwealth University, 2) the Inflammatory Bowel Disease Multi'omic Data (IBDMDB) resource from the Broad Institute and a nation-wide research tam, and 3) Integrated Personal 'Omics Profiling (IPOP) from Stanford University and the Jackson Laboratory for Genomic Medicine. For more information or to get involved with the iHMP, please see http://hmp2.org.

Van Horne A/B
* Curtis Huttenhower, Harvard School of Public Health, USA

Anup Mahurkar, University of Maryland Baltimore, USA

Liang Liang, Stanford University, USA

James P. Brooks, Virginia Commonwealth University, USA

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:15
Personal Medicine and Health (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Diana W. Bianchi, Tufts Medical Center, USA

Leroy E. Hood, Institute for Systems Biology, USA
Systems Medicine and Proactive P4 Medicine: Transforming Healthcare through Wellness—A Personal View

Heidi Rehm, Harvard Medical School, USA
Supporting Genomic Interpretation

Larry Norton, Memorial Sloan Kettering Cancer Center, USA
BCRF Funded Sequencing of Metastatic Breast Cancers

Mark Basik, McGill University, Canada
Short Talk: The DNA Landscape of Drug-resistant Triple Negative Breast Cancer

Haiyuan Yu, Cornell University, USA
Short Talk: Precision Medicine through 3D Interactome Models and Network Perturbation Studies

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2

WEDNESDAY, FEBRUARY 10

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:15
Emerging Themes in Cancer Genomics
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Sohrab Shah, British Columbia Cancer Agency, Canada

Arul M. Chinnaiyan, University of Michigan, USA
Molecular Tumor Board at UMichigan: Progress and Impact

Jeff Tyner, Oregon Health & Science University, USA
Combining Genomic and Functional Screening in Targeted Therapy Decision-Making

Michael F. Berger, Memorial Sloan Kettering Cancer Center, USA
Matching Patients to Treatments through Enterprise-Wide Tumor Sequencing

Marco A. Marra, British Columbia Cancer Agency, Canada
The BC Cancer Agency Personalized OncoGenomics (POG) Project

David Hyman, Memorial Sloan Kettering Cancer Center, USA
New Precision Medicine Clinical Trial Paradigms, Leveraging Cancer Genomics in the Clinic


Following Session is for Genomics and Personalized Medicine (Q2)

08:00—11:15
Personalized and Preventative Medicine
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne C
* Karen B. Avraham, Tel Aviv University, Israel

Robert C. Green, Harvard Medical School/Brigham and Women’s Hospital, USA
Medical, Behavioral and Economic Outcomes in Genomic Medicine

Dennis Wall, Stanford University, USA
Initial Findings from the Whole Genome Sequencing of 3000 Individuals in Multiplex Autism Families

David R. Walt, Tufts University, USA
Single Molecules and Single Cells: Probing Chemistry and Biology at their Fundamental Limit

Jim Kaput, Nestlé Institute of Health Sciences, Switzerland
Developing n-of-1 Experimental Designs for Health Research

Deena Mohamad Ameen Gendoo, Princess Margaret Cancer Centre, Canada
Short Talk: Investigating Pharmacological Drug Classification using Integrative Approaches

Karla Claudio, University of Puerto Rico, USA
Short Talk: Native-American Contribution in Puerto Ricans is Associated with a Lower Warfarin Dose Requirement

09:20—09:40
Coffee Break

Van Horne Foyer
11:15—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Computational and Mathematical Models of Cancer Progression
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Ben J. Raphael, Brown University, USA

Dana Pe'er, Columbia University, USA
Computational Prediction of Driver Genes and Modules

Christina Curtis, Stanford University, USA
Quantifying the Evolutionary Dynamics of Tumor Growth and Progression

Doron Lipson, Foundation Medicine, Inc., USA
Interpreting Cancer Genomes for the Clinician

Margaret L. Hoang, Johns Hopkins University School of Medicine, USA
Short Talk: Accumulation of Somatic Mutations in Normal and Cancerous Tissues with Age


Following Session is for Genomics and Personalized Medicine (Q2)

17:00—19:00
Harnessing Big Data for Health
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne C
* Karin D. Rodland, Pacific Northwest National Laboratory, USA

Atul J. Butte, University of California, San Francisco, USA
Translating a Trillion Points of Data into Therapies, Diagnostics, and New Precision in Medicine

Michael Snyder, Stanford University School of Medicine, USA
Personal Omics Profiing

Kahn Rhrissorrakrai, IBM TJ Watson Research, USA
Short Talk: Watson Genomic Analytics: Literature-informed Dynamic Computational Model for Molecularly Targeted Therapies

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 2

Mezzanine 2

THURSDAY, FEBRUARY 11

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
The Other -Omes (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
Peter A. Jones, Van Andel Research Institute, USA
The Cancer Epigenome

Karin D. Rodland, Pacific Northwest National Laboratory, USA
The Proteogenomic Landscape of Ovarian Cancer: Integrating Genomics and Proteomics in the Context of Clinical Outcome

Joseph R. Ecker, The Salk Institute for Biological Studies, USA
The Personal Epigenome

Jason Wong, University of New South Wales, Australia
Short Talk: Transcription and Differential DNA Repair Underlie Promoter Mutation Hotspots in Cancer Genomes

George I. Mias, Michigan State University, USA
Short Talk: Resources For Integrative Dynamic Omics and Personalized Medicine

09:20—09:40
Coffee Break

Van Horne Foyer
11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—18:45
Single Cell and Liquid Biopsy Genomics of Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne A/B
* Peter A. Jones, Van Andel Research Institute, USA

Nicholas Navin, University of Texas MD Anderson Cancer Center, USA
Investigating Clonal Evolution in Breast Cancer by Single Cell DNA Sequencing

Michael Morrissey, Novartis Institutes for Biomedical Research, USA
Enabling Clinical Trials using cfDNA

Caroline Dive, Cancer Research UK Manchester Institute, UK
Circulating Tumor Cells and Circulating Free DNA Studies of Lung Adenocarcinoma


Following Session is for Genomics and Personalized Medicine (Q2)

17:00—19:00
Translational and Clinical Genomics
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Van Horne C
Howard J. Jacob, HudsonAlpha Institute for Bioltechnology, USA
Advancing Clinical Care with Genomic Tools

Diana W. Bianchi, Tufts Medical Center, USA
Noninvasive Prenatal DNA Sequencing Transforms Care and Detects Occult Malignancies

Philip Awadalla, Ontario Institute for Cancer Research, Canada
Exploiting Large Population Cohorts to Capture Genomic x Environmental Determinants of Chronic Diseases

Gregory D. Poore, Duke University, USA
Short Talk: An Integrative Transcriptomics Model for Predicting Host Molecular Responses to Acute Respiratory Infections

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Van Horne A/B
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Mezzanine 2

FRIDAY, FEBRUARY 12

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Constellation Pharmaceuticals Incyte Corporation
Roche
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Abcam plc Exiqon A/S

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676